AU2021391931A1 - Y box binding protein 1 inhibitors - Google Patents

Y box binding protein 1 inhibitors Download PDF

Info

Publication number
AU2021391931A1
AU2021391931A1 AU2021391931A AU2021391931A AU2021391931A1 AU 2021391931 A1 AU2021391931 A1 AU 2021391931A1 AU 2021391931 A AU2021391931 A AU 2021391931A AU 2021391931 A AU2021391931 A AU 2021391931A AU 2021391931 A1 AU2021391931 A1 AU 2021391931A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021391931A
Other languages
English (en)
Inventor
Arpit DHEERAJ
Sanjay V. MALHOTRA
Dhanir TAILOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Leland Stanford Junior University
Original Assignee
Oregon Health & Science University
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, Leland Stanford Junior University filed Critical Oregon Health & Science University
Publication of AU2021391931A1 publication Critical patent/AU2021391931A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021391931A 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors Pending AU2021391931A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121674P 2020-12-04 2020-12-04
US63/121,674 2020-12-04
US202163256609P 2021-10-17 2021-10-17
US63/256,609 2021-10-17
PCT/US2021/061906 WO2022120242A1 (en) 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors

Publications (1)

Publication Number Publication Date
AU2021391931A1 true AU2021391931A1 (en) 2023-06-29

Family

ID=81853609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021391931A Pending AU2021391931A1 (en) 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors

Country Status (6)

Country Link
US (1) US20240016784A1 (enExample)
EP (1) EP4255426A4 (enExample)
JP (1) JP2023552368A (enExample)
AU (1) AU2021391931A1 (enExample)
CA (1) CA3201032A1 (enExample)
WO (1) WO2022120242A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4554587A4 (en) * 2022-07-12 2026-07-01 Univ Oregon Health & Science ENANTIOMER OF AZOPODOPHYLLOTOXINE DERIVATIVE SU056
US20240180881A1 (en) * 2022-11-17 2024-06-06 National Institute Of Immunology Methods for decreasing resistance to chemotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170342086A1 (en) * 2015-02-26 2017-11-30 Ajay Kumar Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds
WO2017207616A1 (en) * 2016-05-31 2017-12-07 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against y box binding protein (yb-1)
WO2019178091A1 (en) * 2018-03-13 2019-09-19 The Board Of Trustees Of The Leland Stanford Junior University Novel n-hydroxyethyl didehydroazapodophyllotoxins as gbp1 inhibitors and methods of overcoming treatment resistance in cancer
CN116761602A (zh) * 2020-12-04 2023-09-15 俄勒冈健康与科学大学 Y盒结合蛋白质1抑制剂

Also Published As

Publication number Publication date
CA3201032A1 (en) 2022-06-09
WO2022120242A1 (en) 2022-06-09
JP2023552368A (ja) 2023-12-15
EP4255426A1 (en) 2023-10-11
US20240016784A1 (en) 2024-01-18
EP4255426A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
WO2022135346A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
Huang et al. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
He et al. Targeting cullin neddylation for cancer and fibrotic diseases
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
US20160002222A1 (en) Prodrug forms of kinase inhibitors and their use in therapy
CA3133688A1 (en) Compositions and methods for treating cancer
ES2780382T3 (es) Derivados de pirazolopirimidina
US9533969B2 (en) Materials and method for inhibiting replication protein A and uses thereof
KR20180081936A (ko) 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
US20190262319A1 (en) Novel methods for treating cancer
US20260000665A1 (en) Enantiomer of azopodophyllotoxin derivative su056
Bharadwaj et al. STAT3 inhibitors in cancer: a comprehensive update
EP4255426A1 (en) Y box binding protein 1 inhibitors
Gu et al. Discovery of a highly potent and selective MYOF inhibitor with improved water solubility for the treatment of gastric cancer
CN108472376A (zh) 用于治疗癌症的合理组合疗法
CA2739250C (en) Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
WO2019171268A1 (en) New active principles for the treatment of tumours
EP4495121A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
CN116761602A (zh) Y盒结合蛋白质1抑制剂
Chen et al. Design, synthesis and biological evaluation of novel 9-N-substituted-13-alkylberberine derivatives from Chinese medicine as anti-hepatocellular carcinoma agents
EP4132657A1 (en) Compositions and methods for treatment of anticancer-drug resistant cancers
KR20210060642A (ko) 성장 관련 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
ES3034869T3 (en) Tg02 for use in treating gliomas in pediatric subjects
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
KR20220042136A (ko) 복소 고리 화합물